Altimmune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.

CEO

Vipin K. Garg

CEOVipin K. Garg

Employees

Employees59

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1997

Founded1997

Employees

Employees59

ALT Key Statistics

Market cap

463.12M

Market cap463.12M

Price-Earnings ratio

-4.56

Price-Earnings ratio-4.56

Dividend yield

—

Dividend yield—

Average volume

2.25M

Average volume2.25M

High today

$5.87

High today$5.87

Low today

$5.62

Low today$5.62

Open price

$5.63

Open price$5.63

Volume

1.65M

Volume1.65M

52 Week high

$11.16

52 Week high$11.16

52 Week low

$3.55

52 Week low$3.55

ALT News

TipRanks 6d

Altimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide

Altimmune (ALT) announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with...

Analyst ratings

90%

of 10 ratings

Buy

90%

Hold

10%

Sell

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.